ArticleMedicine2026
Causal relationship between sex hormones and ischemic stroke risk: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ischemic stroke (IS) exhibits notable sex-related differences, indicating a potentially important role for sex hormones such as sex hormone-binding globulin (SHBG), estradiol, and testosterone. This study employed 2-sample Mendelian randomization (MR) to investigate the causal relationships between these sex hormones and the risk of IS and its subtypes. Genetic instrumental variables for SHBG, estradiol, and testosterone were obtained from the IEU OpenGWAS database. These instruments were analyzed to assess their causal effects on IS and its subtypes using MR methods. Sensitivity analyses were performed using several complementary MR approaches. SHBG was inversely associated with the risk of IS (OR = 0.92; 95% CI = 0.87-0.97; P = .007) and with the small-artery occlusion subtype (OR = 0.84; 95% CI = 0.75-0.94; P = .002), whereas no associations were observed for the large-artery atherosclerosis or cardioembolism subtypes. No causal effects of estradiol or testosterone on IS were identified. Our findings suggest that higher SHBG levels may reduce the risk of IS and could represent a potential therapeutic target. Further studies are needed to elucidate the mechanisms by which SHBG may confer protection against IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.